Newscast – Page 170 – media

GSK Exercises Option over SPEAR T-cell Therapy Program Targeting NY-ESO

Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, today announced that GlaxoSmithKline plc (LSE:GSK) (NYSE:GSK) has exercised its option under a collaboration and license agreement signed in 2014 to exclusively license the right to research, develop, and commercialize Adaptimmune’s NY-ESO SPEAR T-cell therapy program. Further details will be provided in a conference call scheduled for 8:30 AM EDT this morning; dial-in and webcast details are provided below.
- Source: Globenewswire
- 3,332
- September 11, 2017
cancer Company Insight T-cell
Teleflex to take over NeoTract for $1.1bn

Teleflex has signed a definitive agreement to purchase NeoTract for approximately $1.1bn. According to the deal, Teleflex will pay $725m worth of cash upfront at closing and up to an additional $375m after the achievement of select commercial milestones associated with sales until the end of 2020.
- Source: medicaldevice-network
- 589
- September 8, 2017
aggrement invasive Market Views
Verastem’s Duvelisib Succeeds in Late-Stage Blood Cancer Study

Verastem, Inc. (NASDAQ:VSTM), focused on discovering and developing drugs to improve the survival and quality of life of cancer patients, today reported positive top-line results from the Phase 3 DUO study evaluating the efficacy and safety of duvelisib, a first in class oral dual inhibitor of phosphoinositide 3-kinase (PI3K)-delta and PI3K-gamma, in patients with relapsed or refractory chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL).
- Source: Spjnews
- 798
- September 8, 2017
cancer Clinical Trials CLL inhibitor SLL
Stent Tek Closes Series A Investment Round for its ePATH AVF Device, Aiming to Improve Vascular Access for Haemodialysis

Stent Tek, a medical device company that is developing a minimally invasive catheter system for dialysis patients, announced today it has successfully closed a Series A funding round with investments from two institutional investors.
- Source: prnewswire
- 649
- September 8, 2017
catheter invasive Market Views Series
Sanofi wins tentative FDA nod for Admelog insulin lispro injection

Sanofi announced that the U.S. Food and Drug Administration (FDA) granted tentative approval for Admelog® (insulin lispro injection) 100 Units/mL, a rapid-acting human insulin analog. Admelog is indicated to improve glycemic control in adults and children with diabetes mellitus.
- Source: yahoo
- 800
- September 7, 2017
Company Insight diabetes FDA insulin New Approvals
Merck KGaA Plans Consumer Healthcare Sale After Strategic Review

Germany's Merck KGaA is looking to sell its $1 billion consumer healthcare unit after a group-wide strategic review.
- Source: thestreet
- 660
- September 7, 2017
Company Insight healthcare Market Views Merck
The World’s Largest and Most Powerful X-Ray Laser Just Went Online

The European XFEL is now online. Built to be the world's largest facility to house the most powerful x-ray lasers that can be produced, the XFEL would contribute to a better understanding of molecular and chemical process by imaging particles.
- Source: Futurism
- 595
- September 7, 2017
molecular x-ray XFEL
UK researchers develop medical camera to see through body

Researchers from the University of Edinburgh and Heriot-Watt University in the UK have developed a medical camera that could see through the human body and track endoscopic tools used to evaluate internal conditions.
- Source: medicaldevice-network
- 513
- September 6, 2017
body endoscopic medical camera Researches
FDA holds trials of Cellectis’ cell therapy after patient death

US regulators have placed on hold studies of French drugmaker Cellectis’ CAR-T therapy following a patient fatality.
- Source: news.open-medical
- 635
- September 6, 2017
BPDCN CAR–T Clinical Trials Company Insight CRS
Takeda and Noile-Immune Biotech Collaborate to Advance Next Generation CAR-T Cell Therapy Effective for Solid Tumors

A collaboration to develop next generation chimeric antigen receptor T cell therapy (CAR-T) (RELATED: Kite begins EU trial of CAR–T therapy) was announced by Takeda Pharmaceutical Company Limited (TSE: 4502) and Noile-Immune Biotech Inc..
- Source: Takeda
- 1,003
- September 6, 2017
antigen CAR–T Market Views receptor therapy

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.